Navigation Links
Eisai Enters Agreement to Transfer Its Research Triangle Park Campus to Biogen
Date:7/16/2015

RESEARCH TRIANGLE PARK, N.C., July 16, 2015 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it has entered into a definitive agreement to transfer ownership of its Research Triangle Park (RTP) manufacturing campus to Biogen Inc. This arrangement expands upon the capacity-sharing manufacturing alliance Eisai and Biogen have had in place at the RTP facility since early 2013.

Under this new agreement, Biogen will continue to manufacture oral solid-dose products for Eisai. In addition, Eisai has entered into a new manufacturing agreement whereby Biogen will manufacture Eisai's parenteral products. The property ownership transfer comprises all buildings on the campus. The parenteral facility will be transferred immediately upon closing of the transaction and the oral solid-dose facility will be transferred after the expiration of an existing short-term lease. As part of this arrangement, Eisai anticipates approximately 100 employees will be offered employment at Biogen, effective upon deal closing.  

While Eisai's manufacturing footprint is changing, the company remains committed to having supply chain and manufacturing capabilities in the United States. Eisai will continue to base its global partnership management, quality assurance, supply chain and business support staff in North Carolina to manage a seamless supply chain. These functions will remain on the current RTP campus for a six-month transition period until Eisai has secured new office space. In addition, the company will continue to manufacture product at its facility in Baltimore, MD.  

"The decision to transfer ownership of the RTP campus is part of a global supply chain initiative to optimize Eisai's logistics strategy in support of our long-term business objectives," said Lou Arp, general manager of the Eisai RTP site and president of the Global Oncology Manufacturing Unit for Eisai Inc. "Eisai and Biogen have had a successful alliance for a number of years. We share a patient-centric culture and have compatible values on how we perform our work. This arrangement is a natural fit and complementary to both companies, ensuring the state-of-the-art RTP facility operates at a higher capacity and jobs stay in North Carolina."

"Our mission is to provide high-quality medicines to patients whenever and wherever they need them," said Esther Alegria, senior vice president of Global Manufacturing for Biogen. "Eisai's campus, technology and exceptional staff are a perfect fit to support the strategic growth of our global drug supply network, providing us with greater independence and control, expanding our manufacturing capabilities and ensuring that we can meet future demand for our marketed products and pipeline successes."

The closing of the transaction is subject to certain regulatory approvals.

Eisai Inc.
At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and specialty care (Alzheimer's disease, epilepsy and metabolic disorders). To learn more about Eisai Inc., please visit us at www.eisai.com/US.

Eisai Inc. has affiliates that are part of a global product creation organization that includes R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as a global demand chain organization that includes facilities in Maryland and North Carolina. Eisai's global areas of R&D focus include neuroscience; oncology; metabolic disorders; vascular, inflammatory and immunological reaction; and antibody-based programs.

Eisai Co., Ltd. 
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With over 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including oncology and neurology.

As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries. For more information about Eisai Co., Ltd., please visit www.eisai.com. Media InquiriesInvestor InquiriesSuzanne GroganAlex ScottEisai Inc.Eisai Inc.201-746-2083201-746-2177suzanne_grogan@eisai.comalex_scott@eisai.com Logo - http://photos.prnewswire.com/prnh/20120413/MM87168LOGO


'/>"/>
SOURCE Eisai Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Ivor Macleod Appointed Senior Vice President, Chief Financial Officer and Chief Compliance Officer of Eisai Inc.
2. Eisai to Present New Data on Several Oncology Compounds at ASCO 2015
3. Eisai and Arena Pharmaceuticals Announce Presentation of Lorcaserin HCl Data at Upcoming Medical Meetings
4. Eisai and Arena Pharmaceuticals Complete Registrational Trials of an Extended Release Formulation of Lorcaserin
5. Eisai Presents New Data on Perampanel and Rufinamide at the 68th Annual American Epilepsy Society Meeting
6. Eisais David Martin Elected as National Pharmaceutical Councils Chairman of the Board
7. Eisai and Arena Pharmaceuticals Report Results of an Investigational Phase 2 Trial of Lorcaserin HCl as an Aid for Smoking Cessation
8. Eisai and Arena Pharmaceuticals Announce Presentation of Lorcaserin HCl Data at the American College of Clinical Pharmacy Annual Meeting
9. Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy
10. Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity
11. Eisai Oncology to Present New Research on Eribulin and NEPA at 36th Annual San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2019)... ... 18, 2019 , ... It has long been the practice that training programs ... the zone” in order to deliver their best performance. But, how do you know ... have on an athlete’s physiology, then be able to alter that effect. , Thought ...
(Date:10/17/2019)... ... October 17, 2019 , ... One of the most prominent features on a person is the ... they stick out too far from the skull. This can cause a great deal of ... alter and reduce the appearance of their ears. In order to help patients get the ...
(Date:10/15/2019)... BIRMINGHAM, Ala. (PRWEB) , ... October 14, 2019 , ... ... Johnson in a wrongful death medical malpractice case that breaks records for Lee County. ... chest pains, difficulty breathing, and cough. She had been there just two days earlier ...
Breaking Medicine Technology:
(Date:10/15/2019)... FALLS CHURCH, Va. (PRWEB) , ... October 15, ... ... Combination Products:, Complying with FDA’s Most Recent IFU Guidance , **An FDAnews Webinar**, ... does the recent Instructions for Use (IFU) guidance have on new drug applications ...
(Date:10/11/2019)... TEMECULA, Calif. (PRWEB) , ... October 11, 2019 , ... ... hills of Temecula, CA. The new location has incredible views of the Temecula Valley ... . On 2.5 acres, the new facility offers both private rooms as well as ...
(Date:10/10/2019)... ... October 10, 2019 , ... In attendance at ... excited to hear the significant results of an independent study presented by researchers ... The clinical study poster entitled “The Acute Effects of Citrulline Malate and Bonded ...
(Date:10/8/2019)... CA (PRWEB) , ... October 08, 2019 , ... Dr. ... gum disease in San Jose, CA experience relief from this common and treatable condition. ... in order to save adults from living with uncomfortable symptoms, including tender and bleeding ...
(Date:10/8/2019)... ... October 08, 2019 , ... Over the past three ... a standout in the sports restaurant category by providing a higher-quality product and experience ... fall menu as well as a "RAISE A MUG FOR THE CAUSE" campaign in ...
Breaking Medicine News(10 mins):